NRXP (NRX Pharmaceuticals) Debt-to-Equity : -0.35 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NRX Pharmaceuticals Debt-to-Equity?

NRX Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.68 Mil. NRX Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.99 Mil. NRX Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-18.82 Mil. NRX Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2024 was -0.35.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NRX Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

NRXP' s Debt-to-Equity Range Over the Past 10 Years
Min: -42.92 Med: -0.35 Max: 1.42
Current: -0.35

During the past 4 years, the highest Debt-to-Equity Ratio of NRX Pharmaceuticals was 1.42. The lowest was -42.92. And the median was -0.35.

NRXP's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs NRXP: -0.35

NRX Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for NRX Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Debt-to-Equity Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.02

0.03

1.42

-0.78

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial													-1.62	-0.78	-0.45	-0.42	-0.35

Competitive Comparison of NRX Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, NRX Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NRX Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's Debt-to-Equity falls into.

NRX Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NRX Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.161	+	0)	/	-11.733
	=	-0.78

NRX Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.684	+	2.985)	/	-18.822
	=	-0.35

NRX Pharmaceuticals (NAS:NRXP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NRX Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Executives

Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz	director	C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Jonathan C Javitt	director, 10 percent owner, officer: Chief Scientist	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard	director, officer: Chief Executive Officer	1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt	10 percent owner	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg	officer: Chief Financial Officer	C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof	officer: Chief Comm. & Patient Officer	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault	officer: General Counsel & Secretary	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster	director	C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
Sharon Glied	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Ackerman	director, 10 percent owner, officer: President & CEO	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Big Rock Partners Sponsor, Llc	10 percent owner	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483